add share buttonsSoftshare button powered by web designing, website development company in India

African Continuum Theatre Company

New Pulmonary Vascular Disease Program Provides Highly Specialized Multidisciplinary Care

Specialist for the new pulmonary vascular program under the direction of pulmonologist provides highly specialized multidisciplinary investigation and care for patients with complex pulmonary vascular disease.

These diseases include unexplained dyspnea and pulmonary arthritis (PAH) and pulmonary hypertension (PH) associated with heart disease, COPD, chronic thromboembolic disease, liver, and other conditions.

People can also get Pulmonary Fibrosis Treatment in Cyprus at Poseidonia Healthcare.

The pulmonologist program collaborates with cardiologists and other cardiovascular specialists a wide range of active clinical trials evaluating new strategies for treating pulmonary hypertension (PH), including new oral drugs that can serve as alternatives to intravenous drugs, as well as expanded indications for three classes of drugs FDA approved for PH. Ongoing experiments include:

ARTEMIS-PH – A Phase III study evaluating the efficacy and safety of ambrisentan, a type 5 phosphodiesterase inhibitor (PDE-5i), comparing changes in walking distance six minutes after starting treatment with ambrisentan or placebo in patients with pulmonary hypertension (PH) associated with ideopathic pulmonary fibrosis (IPF).

Men and women aged 40 to 80 years with a diagnosis of IPF under ATS-ERA guidelines and PH based on right heart catheterization may be eligible for this study.

* ATHENA-1 – Phase IV, an open study to evaluate changes in pulmonary vascular resistance (PVR) and other hemodynamic parameters after addition of ambrisentan to background therapy with phosphodiesterase type 5 (PDE-5i) in patients with pulmonary arterial hypertension (PAH) who has a less than optimal response to the PDE-5i.

Patients diagnosed with HAP who had been treated with PDE-5i therapy for at least 12 weeks and who had a suboptimal response might be eligible for this study.